Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Cross Below 200-Day Moving Average – Should You Sell?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.86 and traded as low as $0.55. Marinus Pharmaceuticals shares last traded at $0.55, with a volume of 260 shares trading hands.

Wall Street Analysts Forecast Growth

MRNS has been the subject of a number of research analyst reports. HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Royal Bank of Canada lowered their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. StockNews.com initiated coverage on Marinus Pharmaceuticals in a research note on Saturday. They issued a “sell” rating for the company. Jefferies Financial Group restated a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

The company has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. The stock has a 50-day moving average of $0.48 and a two-hundred day moving average of $0.86.

Institutional Trading of Marinus Pharmaceuticals

Several large investors have recently modified their holdings of the company. Suvretta Capital Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the period. Franklin Resources Inc. lifted its position in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. Beryl Capital Management LLC purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at $2,262,000. abrdn plc lifted its position in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. Finally, Woodline Partners LP lifted its position in Marinus Pharmaceuticals by 84.7% during the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 1,071,410 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.